Diego J Covarrubias, MD | |
3264 N Evergreen Dr Ne, Grand Rapids, MI 49525-9746 | |
(616) 363-7272 | |
(616) 361-5828 |
Full Name | Diego J Covarrubias |
---|---|
Gender | Male |
Speciality | Diagnostic Radiology |
Experience | 26 Years |
Location | 3264 N Evergreen Dr Ne, Grand Rapids, Michigan |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366493678 | NPI | - | NPPES |
29091 | Medicaid | OR | |
029091 | Medicaid | OR |
Facility Name | Location | Facility Type |
---|---|---|
Spectrum Health | Grand rapids, MI | Hospital |
Covenant Medical Center | Saginaw, MI | Hospital |
Ascension Macomb Oakland Hosp-warren Campus | Warren, MI | Hospital |
Bronson Methodist Hospital | Kalamazoo, MI | Hospital |
Lakeland Hospital, St Joseph | St joseph, MI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Advanced Radiology Services Pc | 4284546516 | 235 |
Spartan Radiology Inc | 5698003697 | 179 |
Advanced Radiology Services Pc | 4284546516 | 235 |
Spartan Radiology Inc | 5698003697 | 179 |
Advanced Radiology Services Pc | 4284546516 | 235 |
Spartan Radiology Inc | 5698003697 | 179 |
Advanced Radiology Services Pc | 4284546516 | 235 |
Spartan Radiology Inc | 5698003697 | 179 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
HealthPort, a top-25 company in the healthcare information technology industry, today announced that it is providing a money-back guarantee that its Electronic Health Record (EHR) software, HealthPort EHR, will meet certification requirements for Meaningful Use as set forth in the American Recovery and Reinvestment Act (ARRA) of 2009.
Many U.S. schools are not prepared for bioterrorism attacks, outbreaks of emerging infectious diseases or pandemics, despite the recent 2009 H1N1 influenza pandemic that resulted in more than 18,000 deaths worldwide, Saint Louis University researchers say.
An editorial in the April 6 issue of the Journal of the American Medical Association cautions against estrogen-only hormone therapy in women who have had a hysterectomy because of longstanding evidence that it raises the risk of breast cancer.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
› Verified 9 days ago
Entity Name | Advanced Radiology Services Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1740283324 PECOS PAC ID: 4284546516 Enrollment ID: O20161031000172 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
HealthPort, a top-25 company in the healthcare information technology industry, today announced that it is providing a money-back guarantee that its Electronic Health Record (EHR) software, HealthPort EHR, will meet certification requirements for Meaningful Use as set forth in the American Recovery and Reinvestment Act (ARRA) of 2009.
Many U.S. schools are not prepared for bioterrorism attacks, outbreaks of emerging infectious diseases or pandemics, despite the recent 2009 H1N1 influenza pandemic that resulted in more than 18,000 deaths worldwide, Saint Louis University researchers say.
An editorial in the April 6 issue of the Journal of the American Medical Association cautions against estrogen-only hormone therapy in women who have had a hysterectomy because of longstanding evidence that it raises the risk of breast cancer.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
› Verified 9 days ago
Entity Name | Spartan Radiology Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1932768058 PECOS PAC ID: 5698003697 Enrollment ID: O20210702001217 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
HealthPort, a top-25 company in the healthcare information technology industry, today announced that it is providing a money-back guarantee that its Electronic Health Record (EHR) software, HealthPort EHR, will meet certification requirements for Meaningful Use as set forth in the American Recovery and Reinvestment Act (ARRA) of 2009.
Many U.S. schools are not prepared for bioterrorism attacks, outbreaks of emerging infectious diseases or pandemics, despite the recent 2009 H1N1 influenza pandemic that resulted in more than 18,000 deaths worldwide, Saint Louis University researchers say.
An editorial in the April 6 issue of the Journal of the American Medical Association cautions against estrogen-only hormone therapy in women who have had a hysterectomy because of longstanding evidence that it raises the risk of breast cancer.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Diego J Covarrubias, MD 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525-9746 Ph: (616) 363-7272 | Diego J Covarrubias, MD 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525-9746 Ph: (616) 363-7272 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
HealthPort, a top-25 company in the healthcare information technology industry, today announced that it is providing a money-back guarantee that its Electronic Health Record (EHR) software, HealthPort EHR, will meet certification requirements for Meaningful Use as set forth in the American Recovery and Reinvestment Act (ARRA) of 2009.
Many U.S. schools are not prepared for bioterrorism attacks, outbreaks of emerging infectious diseases or pandemics, despite the recent 2009 H1N1 influenza pandemic that resulted in more than 18,000 deaths worldwide, Saint Louis University researchers say.
An editorial in the April 6 issue of the Journal of the American Medical Association cautions against estrogen-only hormone therapy in women who have had a hysterectomy because of longstanding evidence that it raises the risk of breast cancer.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.
› Verified 9 days ago
Dr. Jon R Henke, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-363-7290 | |
Geoffrey M. Remes, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 Fax: 616-361-5828 | |
Jan L Mourelatos, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-361-5828 | |
Dr. Brendan Michael Banyon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 | |
Dr. Joseph J Junewick, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-363-7290 | |
Keith Alan Morrow, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 Fax: 616-361-5828 | |
Dr. Andrew Kent Moriarity, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 |